Amphera
Phase 1EMPOWERING DENDRITIC CELLS Amphera B.V., a late clinical stage biotechnology company, develops MesoPher cell therapy for the treatment of cancer. Our lead indications are mesothelioma and pancreatic cancer. MesoPher is comprised of autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour
About
EMPOWERING DENDRITIC CELLS Amphera B.V., a late clinical stage biotechnology company, develops MesoPher cell therapy for the treatment of cancer. Our lead indications are mesothelioma and pancreatic cancer. MesoPher is comprised of autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour
Funding History
1Total raised: $20M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile